No Increased Breast Cancer Risk With Menopausal Estrogen in BRCA Carriers
SAN ANTONIO — Menopausal hormone therapy (MHT) did not increase breast cancer risk in women with BRCA mutations, according to a study reported here. In fact, women who used estrogen-only MHT had a significantly lower risk of breast cancer compared with a matched cohort of women who did not use MHT (42.% vs 24.9%). An […]
Study Examines Off-Target Mortality in Cancer Screening
Cancer screening reduced targeted cancer mortality without significantly increasing deaths from other causes. Meta-analysis of 17 studies found a 0.2% increase in off-target mortality rates in screened patients. Results suggest a need to analyze on-target cancer mortality and off-target mortality separately in trials of cancer screening. Screening for cancer reduced targeted cancer mortality without a […]
American Cancer Society rally to reduce cancer burden
Cancer advocates rallied in Springfield this week to call on state lawmakers to improve access to colorectal cancer screenings and to support taxing other tobacco products at an equal rate to cigarettes.
Focused Ultrasound Matches Prostatectomy for Intermediate-Risk Prostate Cancer
LAS VEGAS — Focused ultrasound ablation for prostate cancer proved at least equivalent to radical prostatectomy for failure-free survival, according to a randomized trial reported here. After 3 years of follow-up, treatment failure had occurred in 5.6% of patients treated with focused ablation and 7.9% of the prostatectomy groups. The difference did not achieve statistical […]
Immunotherapy/BCG Combo Boosts EFS in Non-Muscle Invasive Bladder Cancer
LAS VEGAS — Event-free survival (EFS) in high-risk non-muscle invasive bladder cancer (NMIBC) improved significantly when patients received the PD-1 inhibitor sasanlimab in addition to bacillus Calmette-Guérin (BCG), a randomized trial showed. The 3-year EFS increased from 74.8% with standard-of-care BCG induction and maintenance to 82.1% with the addition of sasanlimab. Most of the improvement […]
Unprecedented Response Rates in Non-Responsive, Non-Muscle Invasive Bladder Cancer
LAS VEGAS — Patients with high-risk, treatment-unresponsive non-muscle invasive bladder cancer (NMIBC) had an unprecedented response rate and disease-free survival (DFS) with an investigational intravesical treatment system, data from an ongoing trial showed. Complete responses (CR) occurred in 82.4% of 85 patients treated with TAR-200, a system that delivers gemcitabine directly into the bladder. The […]
PSA and Biomarker Testing Plus MRI Appears to Improve Prostate Cancer Screening
A single round of prostate cancer screening that included a prostate-specific antigen (PSA) test, a kallikrein panel, and an MRI detected one additional high-grade cancer per 196 men and one low-grade cancer per 909 men, according to preliminary results from the Finnish ProScreen randomized trial. The risk difference for the group randomized to the screening […]
Some Cancer Patients Can Find It Hard to Tell Family and Friends
Ever since Anthony Bridges found out he had prostate cancer 6 years ago, he hasn’t stopped talking about it. He told his Facebook friends immediately. Now, the 68-year-old man from Georgia spends time working with others to encourage other men to talk to their doctor about getting screened. Not everyone is as eager to share, […]
Oncologists Express Conflicted Views About AI in Clinical Practice
Patients with cancer do not need a detailed understanding of artificial intelligence (AI), but they should consent to use of AI models during treatment, according to a survey of 204 U.S. oncologists. For the key question of patient consent, 81.4% of the oncologists said patient consent should be required for use of AI models. However, […]
‘Excellent’ Outcomes After Complete Response in Lymph Node-Positive Breast Cancer
Patients with early lymph node-positive breast cancer and pathologic complete response (pCR) after neoadjuvant therapy had similar long-term recurrence rates and survival regardless of the type of adjuvant therapy they received, a Dutch registry study showed. After a median follow-up of 6 years, regional recurrence rates ranged from 3.0-4.1% whether they had conservative axillary surgery […]